Program Description
Our Investigator-Sponsored Trials (IST) program provides support for external clinical research that advances medical and/or scientific knowledge about our products and clinical candidates to enhance patient care. Our current IST portfolio includes programs investigating:
The objective of our IST program is to provide funding and/or study drug for clinical research that will:
To discuss your proposed research or for questions about our process, please contact your regional Medical Science Liaison (MSL) or email us at IST@seagen.com for help identifying the MSL in your region.
Process Outline
For a detailed description of our program, processes, and applicant responsibilities, click Program Overview.
Application and Questions
To apply for an IST related to brentuximab vedotin or tucatinib, please visit our online portal.
To apply for an IST related to enfortumab vedotin research, please visit the Astellas Investigator-Sponsored Research portal. Enfortumab vedotin proposals are reviewed jointly by Seagen and Astellas.
Please email IST@seagen.com with questions about our IST program.
Program Description
Our Translational Research Agreement (TRA) program provides support for non-clinical research projects.
Requests for materials transfer or sponsored research will be considered, with a limited number of projects supported each year. To discuss your proposed research or for questions about our process, please contact your regional Medical Science Liaison (MSL) or email us at translationalresearch@seagen.com for help identifying the MSL in your region.
Process Outline
Project will be reviewed within 90 days and the regional MSL will present the proposal internally.
For questions regarding our process, email us at translationalresearch@seagen.com.
Application and Questions
To apply for a TRA unrelated to enfortumab vedotin, register via our online portal.
To apply for a TRA related to enfortumab vedotin research, please visit the Astellas Investigator-Sponsored Research portal. Enfortumab vedotin proposals are reviewed jointly by Seagen and Astellas.
Please email translationalresearch@seagen.com with questions about our TRA program.
Healthcare professionals in the United States can access recent congress presentations, videos about our science, and more on our medical affairs website.